PSN8 COST-OF-ILLNESS STUDY IN PATIENTS SUFFERING FROM CHRONIC PLAQUE PSORIASIS IN GERMANY  by Kugland, B et al.
786 Abstracts
OBJECTIVES: To estimate direct medical costs and treat-
ment failure rates associated with use of systemic agents
and phototherapy in moderate to severe psoriasis.
METHODS: Patient-level claims data on use of psoria-
sis-related Health care services were obtained from a large
New England payer. Patients with >1 claim listings a 
ICD-9-CM diagnosis code for psoriasis (696.0; 696.1)
were eligible for inclusion. Eligible patients not receiv-
ing systemic treatments (methotrexate, cyclosporin A,
acitretin) or phototherapy (ultraviolet B with or without
tar or petrolatum; psoralen and ultraviolet A [PUVA])
were excluded. Treatment failure was deﬁned as switch
to nonrotational therapy, augmentation with nontopical
therapies, discontinuation following up-titration, or 
discontinuation following hospitalization for psoriasis.
Medical costs included those related to pharmacy
(excluding OTC medication), institutional (inpatient and
outpatient) care, and professional services. Mean costs
within each service category, as well as 99th percentile
costs, were estimated by treatment. RESULTS: A total of
2073 patients were included in the analysis. Over a 1-year
period, approximately 21.7% of patients experienced
treatment failure, with therapy switches accounting for
most occurrences. Mean time to treatment failure ranged
from 3–6 months. Per-patient annual pharmacy costs
were lowest among methotrexate users (US$257) and
highest among cyclosporin users (US$1992). The 99th
percentile of annual pharmacy and institutional costs
exceeded US$10,000, while that of professional service
costs was approximately US$2,500. CONCLUSIONS:
The high variability of direct medical costs among these
patients reﬂects the heterogeneous and chronic nature of
psoriasis. Overall, use of conventional systemic and light
therapies for treatment of moderate to severe psoriasis
was associated with frequent failure and high medical
costs.
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OBJECTIVES: Examining the economic impact of psori-
asis vulgaris during the course of one year and due to a
current skin deterioration (ﬂare). METHODS: A multi-
center, cross-sectional, retrospective, and prospective
cost-of-illness study. Information such as demographic
characteristics, frequency, and number of consulta-
tions, hospitalizations, rehabilitations, out-of-pocket-
expenditures and absence from work were collected by
semi-standardized patient questionnaires and chart
record reviews (12 months retrospectively; 6 weeks
prospectively). Direct, medical and non-medical, and
indirect costs were considered from several perspectives:
patients’, third party payers’ (TPP), societal. Inclusion cri-
teria: moderate to severe chronic plaque psoriasis, age
(18–65 years), ongoing ﬂare, signed informed consent.
RESULTS: Twelve ofﬁce-based dermatologists and 5 out-
patient departments in dermatology hospitals enrolled
227 patients, 56% with moderate and 44% with severe
course of disease. Eighty-six percent of the patients
responded to the questionnaire. Mean age was 47 years,
55% were male. On average, annually TPP reimbursed
€835 per patient. Main cost drivers were prescribed med-
ication (60%) and hospitalization (22%). Patients spent
€596 p.a. mainly for additional treatments (26%) e.g.
alternative therapy, OTC-medication/skin care (29%).
Indirect costs per patient amounted to €1435 p.a., 92%
related to early retirement/unemployment due to psoria-
sis. Total annual costs per patient were €2866, including
€2658 per patient with moderate and €2852 per patient
with severe course of disease. Due to the current ﬂare
32% of the patients received systemic therapy and 61%
were treated exclusively topically and/or with photother-
apy. Direct medical costs (TPP) due to a current ﬂare
amounted to €195 per patient within 6 weeks; including
€449 per patient treated with systemic drugs and €85
treated locally and/or with phototherapy. CONCLU-
SION: Patients and their families bear a sizeable amount
themselves. Also, the burden for TPP and for society is
noticeable. Costs increased remarkably for patients
receiving systemic therapy.
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OBJECTIVES: To estimate the prevalence and the quality
of life of subjects suffering from inﬂammatory dermatitis
(ID) (psoriasis, eczema, atopic dermatitis and urticaria) in
the French population of adults 18 years of age or older.
METHODS: A population-based survey was conducted
among 10,000 adults through personal face to face inter-
views by using the quota sampling method (applied on
age, sex, economic working class and woman working
status). The screening was made by asking the subjects if
they have suffered from one of the 4 ID in the past 12
months or if they have been treated by at least one inﬂam-
matory dermatitis speciﬁc treatment from a pre-deﬁned
list. Subjects answering positively to one of these ques-
tions was considered as a “ID subject”. The quality of life
